Beam Therapeutics is a biotechnology company developing base editing, an investigational class of precision genetic medicines designed to overcome limitations of existing genetic editing approaches. The company employs a combination of delivery technologies, including electroporation, nonviral, and viral modalities, to expand the potential of genetic medicine.
AI named Beam Therapeutics from February 2026 to September 2026.
Brand page for beamtx-com